32 patents currently held
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
5 more records may belong here and await a decision; they are not counted.
The next term ends in Nov 2029. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
5
Ending by 2030
Nov 2029
Next term end
16
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Mar 2034 · High confidence
Also notable
Ends Jul 2032 · High confidence
Also notable
Ends Dec 2032 · High confidence
Novel Compounds and Pharmaceutical Compositions Thereof for the Treatment of Inflammatory Disorders
US 9,249,141
The most cited patent in this portfolio, cited by 51 later US patents, top 10% of utility patents granted in 2016 in our data. Protection runs to 2034.
Novel Compound Useful for the Treatment of Degenerative and Inflammatory Diseases
US 8,802,682
Cited by 32 later US patents, top 25% of utility patents granted in 2014 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2032.
Novel Dihydropyrimidinoisoquinolinones and Pharmaceutical Compositions Thereof for the Treatment of Inflammatory Disorders.
US 8,927,543
Renewed at every maintenance window since the 2015 grant; no more fees are due before its term ends in 2032.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Feb 8, 2027The maintenance fee for 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-Dione Derivatives as Adamts Inhibitors for the Treatment of Osteoarthritis (US 11,718,588) comes due Feb 8, 2027. Unpaid by Aug 9, 2027, it lapses early.
- 1 fee due May 26, 2027The maintenance fee for 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-Dione Derivatives as Adamts Inhibitors for the Treatment of Osteoarthritis (US 10,487,060) comes due May 26, 2027. Unpaid by Nov 26, 2027, it lapses early.
- 2 fees due Jul 7 to 26, 2027 · next Jul 7
- 3 fees due Aug 2 to 25, 2027 · next Aug 2
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
The 5 largest of its 16 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,242,274 | Triazolopyridine Kinase Inhibitors Useful for the Treatment of Degenerative and Inflammatory Diseases In force · High confidence | In force | High confidence | |
| US 8,663,930 | Methods and Means for Treatment of Osteoarthritis In force · High confidence | In force | High confidence | |
| US 9,951,337 | Methods and Means for Treatment of Osteoarthritis In force · High confidence | In force | High confidence | |
| US 8,796,457 | Novel Compound Useful for the Treatment of Degenerative and Inflammatory Diseases In force · High confidence | In force | High confidence | |
| US 9,505,754 | Novel Compound Useful for the Treatment of Degenerative and Inflammatory Diseases In force · High confidence | In force | High confidence | |
| US 8,975,406 | Novel Compound Useful for the Treatment of Degenerative and Inflammatory Diseases In force · High confidence | In force | High confidence | |
| US 9,241,931 | Novel Compound Useful for the Treatment of Degenerative and Inflammatory Diseases In force · High confidence | In force | High confidence | |
| US 9,987,272 | Novel Compound Useful for the Treatement of Degenerative and Inflammatory Diseases In force · High confidence | In force | High confidence | |
| US 8,802,682 | Novel Compound Useful for the Treatment of Degenerative and Inflammatory Diseases In force · High confidence | In force | High confidence | |
| US 8,927,543 | Novel Dihydropyrimidinoisoquinolinones and Pharmaceutical Compositions Thereof for the Treatment of Inflammatory Disorders. In force · High confidence | In force | High confidence |
Also on record, not counted in the 32: 3 applications pending. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.